UMIN ID: UMIN000005191
Registered date:06/03/2011
XELOX stop-and-go trial:A phase 2 study of 1st line chemotherapy for unresectable or recurrent colorectal cancer.
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Unresectable or recurrent colorectal cancer |
| Date of first enrollment | 2010/05/01 |
| Target sample size | 37 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | XELOX therapy 6 courses, followed by XELODA 6 courses, then XELOX |
Outcome(s)
| Primary Outcome | Progression free survival |
|---|---|
| Secondary Outcome | Response rate Time to treatment failure Overall survival Safety plofiles(Rate of Grade 3 neurotoxicity, adverse events) |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 75years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Double cancer, severe allergic history, active infections, severe complications |
Related Information
| Primary Sponsor | Hematology and Oncology, Kyushu University Hospital |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Nothing |
| Secondary ID(s) |
Contact
| public contact | |
| Name | |
| Address | Japan |
| Telephone | |
| Affiliation | Kyushu University Hospital Hematology and Oncology |
| scientific contact | |
| Name | Eishi Baba |
| Address | 3-1-1, Maedashi, Higashi-ku, Fukuokashi Japan |
| Telephone | |
| Affiliation | Kyushu University Hospital Hematology and Oncology |